Literature DB >> 27993955

Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women.

Megha Prasad1, Eric L Matteson1, Joerg Herrmann1, Rajiv Gulati1, Charanjit S Rihal1, Lilach O Lerman1, Amir Lerman2.   

Abstract

Uric acid is a risk factor for coronary artery disease in postmenopausal women, but the association with inflammation and coronary endothelial dysfunction (CED) is not well defined. The aim of this study was to determine the relationship of serum uric acid (SUA), inflammatory markers, and CED. In this prospective cohort study, SUA, high-sensitivity C-reactive protein levels, and neutrophil count were measured in 229 postmenopausal women who underwent diagnostic catheterization, were found to have no obstructive coronary artery disease, and underwent coronary microvascular function testing, to measure coronary blood flow response to intracoronary acetylcholine. The average age was 58 years (interquartile range, 52-66 years). Hypertension was present in 48%, type 2 diabetes mellitus in 5.6%, and hyperlipidemia in 61.8%. CED was diagnosed in 59% of postmenopausal women. Mean uric acid level was 4.7±1.3 mg/dL. Postmenopausal women with CED had significantly higher SUA compared with patients without CED (4.9±1.3 versus 4.4±1.3 mg/dL; P=0.02). There was a significant correlation between SUA and percent change in coronary blood flow to acetylcholine (P=0.009), and this correlation persisted in multivariable analysis. SUA levels were significantly associated with increased neutrophil count (P=0.02) and high-sensitivity C-reactive protein levels (P=0.006) among patients with CED, but not among those without CED. SUA is associated with CED in postmenopausal women and may be related to inflammation. These findings link SUA levels to early coronary atherosclerosis in postmenopausal women.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  acetylcholine; hypertension; inflammation; risk factors; uric acid

Mesh:

Substances:

Year:  2016        PMID: 27993955      PMCID: PMC5233565          DOI: 10.1161/HYPERTENSIONAHA.116.08436

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  76 in total

1.  Assessing coronary endothelial dysfunction.

Authors:  Calin V Maniu; Stuart T Higano; Amir Lerman
Journal:  Circulation       Date:  2002-09-10       Impact factor: 29.690

2.  The association of serum uric acid levels with outcomes following percutaneous coronary intervention.

Authors:  Daniel B Spoon; Amir Lerman; Andrew D Rule; Abhiram Prasad; Ryan J Lennon; David R Holmes; Charanjit S Rihal
Journal:  J Interv Cardiol       Date:  2010-06       Impact factor: 2.279

3.  Coronary endothelial dysfunction is associated with increased risk of venous thromboembolism.

Authors:  Megha Prasad; Robert McBane; Martin Reriani; Lilach O Lerman; Amir Lerman
Journal:  Thromb Res       Date:  2015-12-29       Impact factor: 3.944

4.  Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease.

Authors:  Xiao-Min Dai; Lei Wei; Li-Li Ma; Hui-Yong Chen; Zhuo-Jun Zhang; Zong-Fei Ji; Wan-Long Wu; Ling-Ying Ma; Xiu-Fang Kong; Lin-Di Jiang
Journal:  Clin Rheumatol       Date:  2015-01-29       Impact factor: 2.980

5.  Uric acid is an independent predictor of cardiovascular events in post-menopausal women.

Authors:  Angela Sciacqua; Maria Perticone; Eliezer J Tassone; Antonio Cimellaro; Sofia Miceli; Raffaele Maio; Giorgio Sesti; Francesco Perticone
Journal:  Int J Cardiol       Date:  2015-06-28       Impact factor: 4.164

Review 6.  What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol? An evidence-based review.

Authors:  Marta Guedes; Ana Esperança; Ana Cristina Pereira; Catarina Rego
Journal:  Rev Port Cardiol       Date:  2014-11-20       Impact factor: 1.374

7.  Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension.

Authors:  R Butler; A D Morris; J J Belch; A Hill; A D Struthers
Journal:  Hypertension       Date:  2000-03       Impact factor: 10.190

8.  Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.

Authors:  Leo K Niskanen; David E Laaksonen; Kristiina Nyyssönen; Georg Alfthan; Hanna-Maaria Lakka; Timo A Lakka; Jukka T Salonen
Journal:  Arch Intern Med       Date:  2004-07-26

9.  Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.

Authors:  Johji Nomura; Nathalie Busso; Annette Ives; Chieko Matsui; Syunsuke Tsujimoto; Takashi Shirakura; Mizuho Tamura; Tsunefumi Kobayashi; Alexander So; Yoshihiro Yamanaka
Journal:  Sci Rep       Date:  2014-04-01       Impact factor: 4.379

10.  Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study.

Authors:  Jiunn-Horng Chen; Joung-Liang Lan; Chi-Fung Cheng; Wen-Miin Liang; Hsiao-Yi Lin; Gregory J Tsay; Wen-Ting Yeh; Wen-Harn Pan
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

View more
  24 in total

1.  Study of epidemiological aspects of hyperuricemia in Poland.

Authors:  Katarzyna Kostka-Jeziorny; Krystyna Widecka; Andrzej Tykarski
Journal:  Cardiol J       Date:  2019-06-21       Impact factor: 2.737

2.  Associations of serum uric acid with incident dementia and cognitive decline in the ARIC-NCS cohort.

Authors:  Aniqa B Alam; Aozhou Wu; Melinda C Power; Nancy A West; Alvaro Alonso
Journal:  J Neurol Sci       Date:  2020-04-28       Impact factor: 3.181

3.  Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Di Zhao; Hui Liu; Pingshuan Dong
Journal:  J Hum Hypertens       Date:  2018-11-15       Impact factor: 3.012

Review 4.  Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms.

Authors:  Katie Anne Fopiano; Sawan Jalnapurkar; Alec C Davila; Vishal Arora; Zsolt Bagi
Journal:  Curr Cardiol Rev       Date:  2022

5.  The relationship between uric acid and brain health from observational studies.

Authors:  Xingyao Tang; Zhi-Hui Song; Marly Augusto Cardoso; Jian-Bo Zhou; Rafael Simó
Journal:  Metab Brain Dis       Date:  2022-06-07       Impact factor: 3.655

6.  Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice.

Authors:  Xiaolu Meng; Zhuo Mao; Xin Li; Dandan Zhong; Min Li; Yingli Jia; Jing Wei; Baoxue Yang; Hong Zhou
Journal:  Oncotarget       Date:  2017-06-20

7.  Importance of prognostic value of neutrophil to lymphocyte ratio in patients with ST-elevation myocardial infarction.

Authors:  Jin-Sun Park; Kyoung-Woo Seo; Byoung-Joo Choi; So-Yeon Choi; Myeong-Ho Yoon; Gyo-Seung Hwang; Seung-Jea Tahk; Joon-Han Shin
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

8.  Serum Uric Acid Levels are Associated with Cardiometabolic Risk Factors in Healthy Young and Middle-Aged Adults.

Authors:  Thaís da Silva Ferreira; Julia Freitas Rodrigues Fernandes; Luciene da Silva Araújo; Lívia de Paula Nogueira; Priscila Mansur Leal; Vanessa Parada Antunes; Maria de Lourdes Guimarães Rodrigues; Debora Cristina Torres Valença; Sergio Emanuel Kaiser; Márcia Regina Simas Torres Klein
Journal:  Arq Bras Cardiol       Date:  2018-10-11       Impact factor: 2.000

9.  Comprehensive Metabolic Phenotyping Refines Cardiovascular Risk in Young Adults.

Authors:  Venkatesh L Murthy; Ravi V Shah; Jared P Reis; Alexander R Pico; Robert Kitchen; Joao A C Lima; Donald Lloyd-Jones; Norrina B Allen; Mercedes Carnethon; Gregory D Lewis; Matthew Nayor; Ramachandran S Vasan; Jane E Freedman; Clary B Clish
Journal:  Circulation       Date:  2020-10-19       Impact factor: 29.690

10.  Cardiometabolic Changes in Different Gonadal Female States Caused by Mild Hyperuricemia and Exposure to a High-Fructose Diet.

Authors:  J Soutelo; Y A Samaniego; M C Fornari; C Reyes Toso; O J Ponzo
Journal:  Int J Endocrinol       Date:  2018-08-28       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.